Post-marketing surveillance of Inebilizumab in patients with NMOSD for long-term efficacy and safety
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Inebilizumab (Primary)
- Indications Neuromyelitis optica; Optic nerve disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 11 Jun 2021 New trial record